Injectable HIV prevention drug may be more effective than oral drugs

Embargoed until: Publicly released: 2021-08-12 07:00

International

CC-0

An international trial that compared HIV prevention by injectable PrEP (pre-exposure prophylaxis) drug cabotegravir with prevention by daily orally-taken tenofovir disoproxil fumarate–emtricitabine found the injectable drug was superior in preventing HIV. Over the course of the study, which included 4,566 cis-gender men and transgender women, 13 people on the injectable drug caught HIV, while 39 people on the oral drugs caught HIV. The trial also suggested there are no safety issues with cabotegravir, the scientists add.

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research Massachusetts Medical Society, Web page The URL will go live after the embargo ends

Journal/
conference: NEJM

Research:Paper

Organisation/s: University of California, Los Angeles, USA

Funder: Funded by the National Institute of Allergy and Infectious Diseases and others; HPTN 083 ClinicalTrials.gov number, NCT02720094.)

Media Contact/s

Contact details are only visible to registered journalists.